A more effective treatment for aggressive breast cancer: Two inhibitor drugs show potential
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs ...
Pacylex Pharmaceuticals Presents Progress on NMT Inhibitors for Cancer at February Industry Conferences
Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...
Science Daily2d
Inhibitor drugs to treat aggressive breast cancer identified
A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.
pharmaphorum3d
NICE backs two new breast cancer drugs for NHS use
Piqray (alpelisib) meanwhile is a once-daily, oral PI3K inhibitor that has been cleared ... Other drugs in the class – Gilead Sciences' Zydelig (idelalisib), Bayer's Aliqopa (copanlisib ...
Frontiers4d
miR-133: A Suppressor of Cardiac Remodeling?
Nevertheless, the roles of miR-133 in cardiac remodeling are ambiguous, and the mechanisms are also sophisticated, involving many target genes and signaling pathways, such as RhoA, MAPK, TGFβ/Smad, ...
Frontiers4d
Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis
Thrombotic complications are the second leading cause of death among oncology patients worldwide. Enhanced thrombogenesis has multiple origins and may result from a deregulation of megakaryocyte ...
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...